Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory ...

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the ...

(RTTNews) - Clearmind Medicine Inc. (CMND), Wednesday announced that the company has signed a non-binding Letter of Intent with Polyrizon Ltd. (PLRZ), a development stage biotech company, to develop a ...

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset ...

In addition to associating brain chemicals with depressive states, researchers have found a strong connection with ...